Compare LOAN & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | NSPR |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 38.9M |
| IPO Year | 1999 | 2009 |
| Metric | LOAN | NSPR |
|---|---|---|
| Price | $3.91 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 22.9K | ★ 44.5K |
| Earning Date | 04-16-2026 | 05-04-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $8,666,307.00 | $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | $18.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.88 | $0.63 |
| 52 Week High | $5.79 | $2.57 |
| Indicator | LOAN | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 33.40 |
| Support Level | N/A | $0.69 |
| Resistance Level | $4.15 | $0.72 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.52 | 2.84 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.